MSD’s top-selling immunotherapy Keytruda (pembrolizumab) has secured another approval from the European Commission, this time in the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in patients whose tumours express PD-L1.
Phase 3 data supporting the application demonstrated that Keytruda significantly improved overall survival compared with standard treatment (cetuximab with carboplatin or cisplatin plus 5-FU), either as a monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy.
![[branded content] De vijf belangrijkste customer experience trends voor 2024](https://www.pharmamarketeer.nl/wp-content/uploads/2024/04/customer-experience-80x60.jpg)
